ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1902

Characterization Of HLA-DRB1 Distribution By 3rd Hypervariable Region Sequence In Systemic Sclerosis and Control Populations

Coline, A. Gentil1, Hilary S. Gammill1, Christine, T. Luu1 and J. Lee Nelson2, 1Immunogenetics, Fred Hutchinson Cancer Research Center, SEATTLE, WA, 2Immunogenetics D2-100, Fred Hutchinson Cancer Rsch, Seattle, WA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, Epigenetics and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

HLA class II genes are associated with a wide spectrum of autoimmune diseases.  Specific alleles at the DRB1, DQA1 and DQB1 loci are associated with systemic sclerosis (SSc) risk and/or clinical characteristics such as autoantibody profile. HLA nomenclature, particularly for the HLA-DRB1 locus, evolved utilizing serological typing reagents resulting in “a language of HLA” with initial grouping based primarily on antibody recognition of the HLA molecule.  However, the third hypervariable region (3rd HVR) is the important site for T cell recognition, and the T cell perspective may be more important for autoimmune diseases including SSc. We therefore conducted an analysis based on the different amino acid sequences of the 3rd HVR (aa 67-74) irrespective of the HLA allele group.  We sought to test the hypotheses that 1) overall charge of the amino acids in the 3rd HVR (positive, neutral or negative) differs for SSc patients compared to controls and 2) 3rd HVR charge differs for maternally-inherited vs. paternally-inherited HLA-DRB1 alleles.

Methods:

We studied 254 control women and 133 women with SSc. HLA genotyping for DRB1 was performed by a PCR sequence-specific oligonucleotide probe method. Family studies were conducted to determine which HLA haplotype was maternally- or paternally-inherited. The data were then categorized according to which of 24 different 3rd HVR sequences was encoded by each allele. Next the 3rd HVR sequences were grouped according to whether they resulted overall in a positive, neutral or negative charge. Analyses were done by chi square. 

Results:

The overall distribution of the 3rd HVR sequences was significantly different in the SSc compared to the control population (p=0.0005), a difference primarily driven by enrichment of the FLED sequence present in the DRB1*1104 allele among the SSc population (p=0.001). No difference was observed for the overall 3rd HVR charge comparing the two populations.  However, interestingly, among SSc patients, 3rd HVR charge differed by maternal vs. paternal haplotype (p=0.0001), a difference not seen among controls. 

Conclusion:

We observed a significant difference in the distribution of HLA-DRB1 alleles when classified according to the 3rd HVR, and especially an enrichment of the FLED sequence among SSc patients compared to controls. This result indicates a possible role for 3rd HVR amino acid sequences in SSc. Polymorphism of amino acid sequences in the 3rd HVR can result in overall differences in charge. Our surprising observation of a significantly skewed distribution of 3rd HVR charge in maternal vs. paternal HLA haplotype in SSc patients but not in controls suggests a potential epigenetic effect that could contribute to SSc pathogenesis. 

Acknowledgement: We are very grateful for support of this work from the Scleroderma Foundation.


Disclosure:

C. A. Gentil,
None;

H. S. Gammill,
None;

C. T. Luu,
None;

J. L. Nelson,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-hla-drb1-distribution-by-3rd-hypervariable-region-sequence-in-systemic-sclerosis-and-control-populations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology